A MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, MULTI-ARM HISTORICAL CONTROL, COMPARATIVE TRIAL OF THE SAFETY AND EFFICACY OF HYDROXYCHLOROQUINE AND THE COMBINATION OF HYDROXYCHLOROQUINE AND FAMOTIDINE FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 DISEASE

  • Funded by Biomedical Advanced Research and Development Authority (BARDA)
  • Total publications:0 publications

Grant number: 75A50120C00078

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2020
  • Known Financial Commitments (USD)

    $20,747,018
  • Funder

    Biomedical Advanced Research and Development Authority (BARDA)
  • Research Location

    United States of America
  • Lead Research Institution

    ALCHEM LABORATORIES CORPORATION
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation
  • Research Subcategory

    Clinical trial (unspecified trial phase)
  • Special Interest Tags

    N/A
  • Study Type

    Clinical
  • Clinical Trial Details

    Randomized Controlled Trial
  • Broad Policy Alignment

    Pending
  • Age Group

    Unspecified
  • Vulnerable Population

    Unspecified
  • Occupations of Interest

    Unspecified

Abstract

A MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, MULTI-ARM HISTORICAL CONTROL, COMPARATIVE TRIAL OF THE SAFETY AND EFFICACY OF HYDROXYCHLOROQUINE AND THE COMBINATION OF HYDROXYCHLOROQUINE AND FAMOTIDINE FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 DISEASE